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Abstract
The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder forms of
cognitive impairment, having surpassed the well-known limitations of the MMSE. The aim of the present study was to
validate the MoCA as well as its short version, which was proposed by the NINDS-CSN VCI Harmonization Standards
for screening Vascular Dementia (VaD) patients. The results, based on a homogeneous sample of 34 VaD patients,
indicate that the MoCA is a psychometrically valid and reliable instrument for cognitive screening in VaD patients,
showing excellent discriminant validity. Both the full and short versions of the MoCA had excellent diagnostic accuracy
in discriminating VaD patients, exhibiting an area under curve (AUC) higher than the MMSE [AUC(MoCA full
version)5 .950; 95% IC5 .868–.988; AUC(MoCA short version)5 .936; 95% IC5 .849–.981; AUC(MMSE)5 .860;
95% IC5 .754–.932]. With a cutoff below 17 on the MoCA full version and 8 on the short version, the results for
sensitivity, specificity, positive and negative predictive values, and classification accuracy were superior compared to
the MMSE. In conclusion, both versions of the MoCA are valid, reliable, sensitive and accurate screening instruments
for VaD patients. (JINS, 2012, 18, 1031–1040)
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INTRODUCTION
In recent years, the nosologic concept of vascular cognitive
impairment and dementia has generated a huge controversy
and disagreement regarding diagnostic criteria. The existence
of many cases of cognitive deficit resulting from cere-
brovascular disease but not fulfilling the criteria for dementia
has led to the recent emergence of a broader concept named
Vascular Cognitive Impairment (VCI; Hachinski & Bowler
1993; O’Brien, Reisberg, & Erkinjuntti, 2003). In this
context, three diagnostic categories are mainly proposed:
Vascular Mild Cognitive Impairment (vMCI, also known as
Vascular Cognitive Impairment No Dementia, VCIND),
Vascular Dementia (VaD), and mixed dementia (Moorhouse
& Rockwood, 2008; O’Brien et al., 2003).
The concept of VaD, which is classified as a VCI subtype,
was introduced in the 1990s (Roma´n et al., 1993), replacing
the previous concepts of Cerebral Arteriosclerosis and
Multi-infarct dementia (Hachinski, Lassen, & Marshall,
1974). This concept’s evolution was associated with the
proposal of new diagnostic criteria for Vascular Dementia
by the National Institute of Neurological Disorders and
Stroke – Association Internationale pour la Recherche
et l’Enseignement en Neurosciences (NINDS-AIREN; Roma´n
et al., 1993). These criteria were organized and further
operationalized by van Straaten and collaborators (2003),
considering three fundamental axes of diagnosis: (a) presence
of dementia, confirmed by neuropsychological assessment;
(b) clinical and imaging evidence of cerebrovascular disease;
and (c) establishment of a causal relationship between
the vascular lesions and the emergence or aggravation of
the cognitive deficits. The harmonization and coverage of
clinical, neuroimaging, and anatomic-pathologic data makes
these diagnostic criteria much more objective and selective
than previous ones, namely the old Hachinski ischemic score
(Hachinski et al., 1975), explaining why they have gathered
more consensus in clinical practice, becoming the most
widely used in research (Santana, 2006).
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Epidemiological studies, although not consistent, have
generally reported that VaD is the second most common
cause of dementia, after Alzheimer’s disease (AD) (Canadian
Study of Health and Aging Working Group, 1994; Lobo,
Martinez-Lage et al., 2000). In Europe, the prevalence rate is
approximately 16/1000 in people over 65 years old, repre-
senting approximately 20% of all dementia cases (Ikeda
et al., 2001; Lobo, Launer et al., 2000). Moreover, in some
Asian countries, VaD appears to be more prevalent than AD
(Ikeda et al., 2001; Ueda, Kawano, Hasuo, & Fujishima,
1992). Both prevalence and incidence of VaD and AD
increase exponentially with age, and even though the increase
in VaD seems to be less steep than for AD, the prevalence
rate for individuals over 100 years old surpasses 52/1000
(Jorm & O’Brien, 2004; Lobo, Launer et al., 2000).
This high prevalence of VaD, highlight the importance of
an accurate clinical identification of this disease. Moreover,
this purpose is generally acknowledged to be difficult, largely
because of the clinical features of VaD (Garrett, Paul, Libon
& Cohen, 2004; Reed et al., 2004). The clinical features of
the vascular cognitive impairment reflect the location, num-
ber, and extent of underlying ischemic, hemorrhagic, or
hypoperfusion lesions (Desmond, 2004; Ueda et al., 1992).
As a result of this heterogeneity in mechanisms, vascular
territory involvement and location, cognitive impairment in
VaD is highly variable and potentially affects all cognitive
domains. Despite this, the preponderant neuropsychological
features of VaD patients point to an overall profile of cognitive
dysfunction that is frontally located in the brain, due to the early
involvement of executive cortico-subcortical circuits (O’Brien
et al., 2003; Roma´n, 2003; Roma´n & Royall, 1999). The
dysexecutive syndrome has been recurrently associated with
the vascular clinical conditions (Desmond, 2004; Lamar, Price,
Giovannetti, Swenson, & Libon, 2010). Additionally, cortical
functions such as language, calculation, and orientation tend to
be relatively preserved, in contrast with AD patients (Looi &
Sachdev, 1999; Roma´n & Royall, 1999). Deficits in recent
episodic memory are usually less severe in VaD patients than
in degenerative dementias, while concentration difficulties,
working memory dysfunction, and psychomotor slowing are
early and prominent symptoms in VaD (Looi & Sachdev,
1999; O’Brien et al., 2003; Roma´n, 2003).
An additional factor for this difficult to diagnose VaD
refers to the insufficient breadth of representation of the
cognitive abilities relevant to cognitive impairment asso-
ciated with the disease in cognitive assessment tools, an
essential condition for the accurate cognitive recognition
and assessment (Mungas, Reed, & Kramer, 2003). In fact,
traditional screening tools frequently do not include measures
of important domains initially impaired in VaD, mainly the
executive functions, or the evaluation is very superficial
using low complex tasks. This is the case of the Mini Mental
State Examination (MMSE; Folstein, Folstein, & McHugh,
1975), which is the most widely used cognitive screening
instrument for dementia, despite its well-known limitations;
namely, it has low sensitivity to milder forms of cognitive
impairment and does not evaluate executive functioning
(Freitas, Santana, & Simo˜es, 2010; Ihl, Fro¨lich, Martin, &
Maurer, 1992; Tombaugh & McIntyre, 1992; Wind et al.,
1997). These issues, according to several experts, are espe-
cially relevant for dementias such as VaD that present
prominent executive impairment (Hachinski et al., 2006;
Martinic´-Popovic´, Sˇeric´, & Demarin, 2006; Pendlebury,
Cuthbertson, Welch, Mehta, & Rothwell, 2010; Pirscoveanu
et al., 2009; Roma´n, 2003).
The Montreal Cognitive Assessment (MoCA; Nasreddine
et al., 2005) is a cognitive screening test specifically devel-
oped for the screening of milder forms of cognitive impair-
ment. Surpassing the limitations of the MMSE and proving
be a more useful, sensitive and accurate measure, the MoCA
is now recognized as one of the best cognitive screening
tests (Gauthier et al., 2011; Ismail, Rajji, & Shulman,
2009; Jacova, Kertesz, Blair, Fisk, & Feldman, 2007; Lonie,
Tierney, & Ebmeier, 2009). Currently, the MoCA is an
extensively validated screening tool for many disorders; it
displays good overall psychometric properties and improved
sensitivity to cognitive decline, which contributed to its rapid
international recognition. This improved sensitivity in rela-
tion to other measures is related to the MoCA’s more com-
prehensive assessment of major cognitive domains, including
executive function, short-term memory, languages abilities,
and visuospatial processing. Considering the qualities and
adequacy of the MoCA, the neuropsychology working group
of the NINDS-CSN VCI Harmonization Standards criteria
(Hachinski et al., 2006), recommends using the abbreviated
version of the MoCA (12 items—hereinafter referred as
MoCA short version) for brief cognitive screening in vascular
patients in special settings such as primary health care, large
epidemiological studies or clinical trials. This proposed 5-min
protocol may be administered by telephone and is composed
of three subtests: a five-word immediate and delayed recall
test, a six-item orientation task, and a phonemic fluency test.
Several studies have been conducted to investigate cere-
brovascular and cardiovascular diseases using the MoCA full
version (Aggarwal & Kean, 2010; Cumming, Bernhardt, &
Linden, 2011; Dong et al., 2010; Ihara, Okamoto, & Takahashi,
2012; Pendlebury et al., 2010; Pirscoveanu et al., 2009; Wong
et al., 2008; 2009). All of these studies indicate that the MoCA
is a psychometrically valid, reliable and sensitive cognitive
screening test for the mentioned clinical conditions. Thus far,
however, there are few previous studies using a homogeneous
group of VaD patients to confirm those results and no studies of
validation of the MoCA short version.
The aim of the present study was to investigate the validity
of the MoCA (Nasreddine et al., 2005; Simo˜es et al., 2008)
for cognitive screening of VaD patients. The psychometric
properties and diagnostic accuracy of the MoCA was analyzed
and the optimal cutoff points to detect VaD patients were
established. In parallel, the same analysis was conducted for
the short version of the MoCA proposed by NINDS-CSN VCI
Harmonization Standards (Hachinski et al., 2006). Further-
more, we also aimed to investigate the cognitive performance
of the VaD patients on the MoCA’s cognitive domains and
analyze the differences with comparison to AD patients.
1032 S. Freitas et al.
METHODS
Participants and Procedures
The study sample was composed of 102 participants
distributed between three subgroups: (I) a VaD group with
34 patients, (II) an AD group with 34 patients, and (III)
a Control group with 34 cognitively healthy adults. The
demographic data of the participants in each group are
summarized in Table 1.
The VaD patients were recruited between January 2009
and June 2011 at the Dementia Clinic of the Neurology
Department of Coimbra University Hospital (Coimbra,
Portugal) and included only patients with a diagnosis of
probable VaD, based on international criteria (Roma´n et al.,
1993). Patients with Vascular Mild Cognitive Impairment
(vMCI), also called Vascular Cognitive Impairment no
Dementia (VCIND), or with mixed dementia were not
included. Eligibility was based on a comprehensive clinical
evaluation, which included a neuropsychological and imaging
study, and the final diagnosis was established by a multi-
disciplinary team consensus composed by two neurologists,
two neuropsychologists and two neuroradiologists with
expertise in dementia investigation.
The AD group included the patients with a diagnosis of
probable AD, as previously established by a multidisciplinary
team consensus using international criteria (American Psychia-
tric Association, 2000; McKhann et al., 1984). This diagnosis
subgroup excluded patients with significant vascular disease,
using either clinical or imaging evaluations. This group was
selected from among the AD patients of the Dementia Clinic of
the Neurology Department of Coimbra University Hospital
(Coimbra, Portugal) to match VaD patients on gender, age,
educational level, and severity of cognitive decline, as assessed
by the MMSE (Folstein et al., 1975).
All patients were clinically examined by a neurologist
(I.S.), and a standard investigation was always performed,
including routine laboratory exams and analyses (Apolipo-
protein E [APOE] genotyping and imaging studies: structural
(computed tomography [CT] and/or magnetic resonance
imaging [MRI]) and functional (single photon emission CT
[SPECT]). PET and cerebrospinal fluid analyses were carried
out more restrictively, although they were considered in
younger patients and whenever the suspicion of an inflam-
matory, infectious, or neoplastic brain involvement was
raised. Structural imaging studies, namely CT or MRI, were
fundamental in the differential diagnosis of dementia patients
in this study. In accordance with the inclusion criteria for
VaD and the exclusion criteria for AD, the following findings
were relevant: (1) evidence of large cortico-subcortical
infarcts; (2) extensive periventricular (PVL) or subcortical
white matter lesions (SCWML), affecting more than 25% of
the volume of the supra-tentorial white matter (WML), based
on a CT or MRI volumetric qualitative analysis; (3) uni- or
bilateral thalamic strokes; (4) lacune in the head of the
caudate nucleus or in the inferior genu of the internal capsule;
(5) more than two lacunes. At the outset of this study, the
following were also considered exclusion criteria for
patients’ selection: (1) an unstable clinical condition, with
significant comorbidities; (2) high dementia severity (only
including patients with CDRr 2 and MMSEZ 12 points);
(3) recent pharmacotherapy changes (patients on stable
medication (. 6 months) with cholinesterase inhibitors or
psychotropic drugs were allowed to enter the study, but
recent dose changes of these drugs, as well as introduction of
medication with anti-cholinergic effect were considered
an exclusion criteria); (4) recent psychiatric comorbidity
(clinically diagnosed in the 6 months before the current
neuropsychological evaluation); and (5) significant motor,
visual or auditory deficits, all of which may influence
neuropsychological assessment. For each patient considered
suitable for the study at the time of data collection, a diagnosis
was recorded in the clinical file by the neurologist.
All patients also underwent a comprehensive neuro-
psychological assessment battery including the following
instruments: the MMSE (Folstein et al., 1975), the Alzheimer’s
Disease Assessment Scale (ADAS; Rosen, Mohs, & Davis,
1984), the Clinical Dementia Rating scale (CDR; Hughes,
Berg, Danziger, Coben, & Martin, 1982), the Irregular
Word Reading Test (TeLPI; Alves, Simo˜es, & Martins,
2009), the Subjective Memory Complaints scale (SMC;
Schmand, Jonker, Hooijer, & Lindeboom, 1996), and the
Geriatric Depression Scale (GDS-30; Yesavage et al., 1983).
The MoCA was never used for diagnostic purposes.
The control group was composed of cognitively healthy
members of the community, living in Portugal. This group
was selected from the database of the MoCA’s normative
study for the Portuguese population to match each patient on
variables that were found to be predictive of the MoCA’s
performance (educational level and age; Freitas, Simo˜es,
Alves, & Santana, 2011), and additionally on gender. Details
of the controls’ recruitment procedure, inclusion and exclu-
sion criteria, and neuropsychological assessment have been
described in a previous study (Freitas et al., 2011).
An informed consent was obtained from all the participants
after the research aims, procedures, and confidentiality
requirements were fully disclosed by a member of the
research team. For the patients who were not capable
of providing the informed consent, a legal representative
Table 1. Demographic and clinical characteristics of the subgroups
VaD AD Control
n 34 34 34
Gender 12 (35.3) 12 (35.3) 12 (35.3)
Age 73.216 7.85 74.006 7.36 73.656 7.40
Educational Level 4.976 2.747 5.096 2.54 5.096 2.82
MMSE score 24.066 4.01 23.246 4.21 27.946 1.41
MoCA score 13.066 4.62 11.476 4.24 22.976 3.38
Note. Gender is characterized by female’s n and respective percentage (%).
Data of other variables are presented as mean6 standard deviation.
VaD5 group of patients with Vascular Dementia; AD5 group of
patients with Alzheimer0s disease; Control5 group of cognitively healthy
adults; MoCA5Montreal Cognitive Assessment (maximum score5 30);
MMSE5Mini Mental State Examination (maximum score5 30).
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fulfilled that requirement on their behalf. The present
research complied with the ethical guidelines for human
experimentation stated in the Declaration of Helsinki and
was approved by the Ethics Board of Coimbra University
Hospital, by the ‘‘Fundaça˜o para a Cieˆncia e Tecnologia’’
[Portuguese Foundation for Science and Technology] and
by the Faculty of Psychology and Educational Sciences
Scientific Committee.
Material and Neuropsychological Testing
Each participant was assessed in a single session by a
neuropsychologist experienced in evaluating patients with
dementia. In the clinical interview, the demographic and
clinical data were collected through a complete socio-
demographic questionnaire, an inventory of past habits and
of the current clinical health status as well as of the medical
history. Following this, the same neuropsychologist admi-
nistered the MMSE (Folstein et al., 1975; Guerreiro, 1998)
and the MoCA (Nasreddine et al., 2005; Simo˜es et al., 2008),
in that fixed order, to all subjects. Both the MMSE and the
MoCA are in paper-and-pencil format and are scored out of a
possible total of 30 points, with higher scores indicating
better cognitive performance. The MoCA was developed to
screen milder forms of cognitive impairment through the
assessment of six cognitive domains: (1) executive functions;
(2) visuospatial abilities; (3) short-term memory; (4) language;
(5) attention, concentration, and working memory; and
(6) temporal and spatial orientation (Nasreddine et al., 2005).
In the current study, the MoCA’s total score refers to the raw
score without any correction points for education effects.
Nasreddine and collaborators (2005) suggest a correction point
for individuals with 12 or less years of education. However,
the Portuguese population has a considerable lower education
level in comparison with the original study population. Due to
this major difference, the correction point is not entirely
applicable to the Portuguese population. The norms for the
Portuguese population were calculated and stratified according
to different educational levels (Freitas et al., 2011).
Statistical Analysis
Statistical analyses of the data were carried out using
the Statistical Package for the Social Sciences (SPSS, version
19.0) (IBM SPSS, Chicago, IL). Descriptive statistics
were used for the sample’s characterization. The w2 test, the
two-sample t test, the one-way between-groups analysis
of variance (ANOVA), and the Tukey HSD and Bonferroni
post hoc test were conducted to explore group differ-
ences. The Cronbach’s alpha was considered as an index of
internal consistency. The Pearson correlation coefficients
were used for analyses of convergent validity, and to explore
the correlations between items, cognitive domains and
total scores.
The diagnostic accuracy of the MoCA and the MMSE for
the prediction of the clinical diagnosis of VaD was assessed
through the receiver operating characteristics (ROC) curve
analysis, implemented in MedCalc (version 11.6) (MedCalc
Software, Mariakerke), with larger areas under the curve
(AUC) indicating better diagnostic accuracy. The ROC
curves were compared according to the AUC comparison
method of Hanley and McNeil (1983). The optimal cutoff
points for each screening instrument that yielded the highest
Youden index were selected, with higher Youden indices
indicating maximum sensitivity and specificity. To analyze
the predictive value of the tests, for each cutoff point, we
calculated the sensitivity (the probability of subjects with
cognitive impairment having a positive result), specificity
(the probability of subjects without cognitive impairment
having a negative test), positive predictive value (PPV, the
probability of disease in subjects with a positive result),
negative predictive value (NPV, probability of a ‘‘lack of
disease’’ classification in subjects with a negative result), and
classification accuracy (probability of correct classification of
subjects, with or without cognitive impairment).
RESULTS
Sample Characterization
The characteristics of the study sample, and in more detail of
all subgroups, are presented in Table 1. For this description,
were considered: sample size, gender, age, educational level,
MMSE score, and MoCA score.
As mentioned above, the participants in the three groups
were matched based on gender, age, and educational level.
Additionally, the VaD and AD patients were also matched
based on their MMSE scores. In fact, as seen on Table 1,
there are no gender differences between the three groups.
Likewise, no statistically significant differences were found
based on age (F(2,99)5 .095; p5 .910) or educational level
(F(2,99)5 .021; p5 .979). Furthermore, statistically sig-
nificant differences in MMSE scores were not observed
between clinical groups (t(66)5 .826; p5 .412), which
suggests similarities in terms of cognitive decline severity.
Psychometric Properties
Cronbach’s alpha of the MoCA as an index of internal
consistency was 0.908 for the total study sample, confirming
the overall reliability of the scale when used to examine
Portuguese subjects. Regarding the analysis of MoCA items
that could be eliminated to increase consistency, the results
indicated that none should be excluded. This reliability
coefficient was also computed for each clinical group:
a (VaD)5 .825 and a (AD)5 .806. The respective values
for the MMSE were: a (total sample)5 .807, a (VaD)5 .771,
and a (AD)5 .804.
The correlations between the MoCA scores and the MMSE
scores were significant and positive in the total sample
(r5 .741; p, .001) and in the VaD group (r5 .782; p, .001),
which is indicative of convergent validity. Regarding to the
MoCA cognitive domains, we found significant and positive
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correlations between each cognitive domain score and the
total score of the scale for all three groups (Table 2), which
is suggestive of construct-related validity. Additionally,
regarding the correlation coefficients of each item within the
cognitive domains, overall items showed a significant and
positive correlation with the respective domain. The excep-
tions are the camel, second subtraction, place, and city items,
which showed no significant correlation with any domain due
to the lower variance of the results (hit rates: camel5 79.4;
second subtraction5 23.5; place5 97.1; city5 100). Further-
more, the cube’s copy showed a significant correlation with
the visuospatial domain (r5 .452; p, .001) and with the
executive function domain (r5 .491; p, .001).
Group Differences
Comparing the MoCA total scores of the three groups, statisti-
cally significant differences can be observed (F(2,99)5 78.121;
p, .001). However, according to post hoc tests, these differ-
ences occurred between the control group and both clinical
groups, with higher performance seen in the healthy partici-
pants. No differences were found between VaD and AD
groups, which were previously matched based on their MMSE
scores. As expected, a more detailed analysis regarding sub-
scores of the MoCA cognitive domains revealed that the
healthy participants had higher performances in all cognitive
domains than both clinical groups. The scores on the cognitive
domains for all three groups are presented on Table 3. There
were no statistically significant differences between the VaD
and AD patients at the level of the cognitive domains of the
MoCA, nor at the level of some tasks’ sub-scores, such as
clock drawing, naming tasks, subtraction, and abstraction
tasks. Additionally, no differences in the number of the words
stated in the phonemic fluency task were found.
Considering the abbreviated version of the MoCA proposed
by the NINDS-CSN VCI Harmonization Standards criteria
(Hachinski et al., 2006) as a 5-min protocol (total score5 12),
no statistically significant differences were found between
VaD (5.506 1.93) and AD patients (4.656 1.89). Never-
theless, the short version of the MoCA discriminates control
subjects (9.326 1.408) from both clinical groups, according to
the post hoc tests (F(2,99)5 68.295; p, .001).
Cutoff Points
The receiver operating characteristics (ROC) curve analysis
and the predictive values were computed to evaluate the
diagnostic accuracy of MoCA to discriminate VaD patients
from cognitively healthy adults. First, the diagnostic accu-
racy of the MoCA full version was compared with the diag-
nostic accuracy of the MMSE; second, the MoCA short
version was compared with the MMSE; and then, the
MoCA full version was compared with the short version
(Hachinski et al., 2006).
The MoCA full version discriminant potential for
VaD was excellent, with an AUC of .950 (95% confidence
interval5 .868–.988), while the MMSE demonstrated an
AUC of .860 (95% confidence interval5 .754–.932). These
AUCs are significantly different (Z5 2.142; p5 .0322),
according to the AUC comparison method of Hanley and
McNeil (1983), indicating different classificatory accuracy of
the instruments. Graphic representations of the ROC curves
are provided in Figure 1. Similarly, the MoCA short version
also reveals an excellent discriminant potential for VaD with
an AUC of .936 (95% confidence interval5 .879–.992),
although not significantly different from the MMSE results
(Z5 1.774; p5 .076), according to the AUC comparison
method of Hanley and McNeil (1983). The respective graphic
representations of the ROC curves are provided in Figure 2.
Table 2. Correlations of the scores on cognitive domains and the
MoCA total score
VaD AD Control
Executive Functions .669** .453** .679**
Visuospatial Abilities .619** .428* .664**
Memory .495** .458** .287*




Orientation .556** .698** .463**
Note. VaD5 group of patients with Vascular Dementia; AD5 group of
patients with Alzheimer0s disease; Control5 group of cognitively healthy
adults; MoCA5Montreal Cognitive Assessment.
**p, .01.
* p, .05.
Table 3. Scores on the cognitive domains
VaD AD Control
Executive Functions 0.596 0.988 0.596 0.657 2.156 1.019
Visuospatial Abilities 1.416 0.892 1.246 0.606 3.096 1.055
Memory 0.596 1.019 0.296 0.676 3.096 1.379
Language 2.856 1.282 2.386 1.457 4.246 1.281
Attention, Concentration, and Working Memory 2.856 1.760 2.796 1.647 4.856 1.209
Orientation 4.826 1.267 4.246 1.437 5.886 0.327
Note. VaD5 group of patients with Vascular dementia; AD5 group of patients with Alzheimer0s disease; Control5 group of
cognitively healthy adults.
Data are presented as mean6 standard deviation.
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Nevertheless, in both comparisons it can be observed that
the MoCA’s ROC curves (full and short versions) fully
include the curve for the MMSE; this is a clear indication that
there is always a cutoff for the MoCA, with higher sensitivity
and specificity, for any cutoff chosen for the MMSE.
Comparing the AUCs of the MoCA full and short versions
(AUC5 .936; 95% confidence interval5 .849–.981), no
statistically significant differences were found (Z5 .488;
p5 .6256), according to the AUC comparison method
of Hanley and McNeil (1983). Graphic representations
of the respective ROC curves are provided in Figure 3. The
optimal cutoff points for maximum accuracy (Youden index)
and the respective values of sensitivity, specificity, PPV,
NPV, and classification accuracy are described for both
instruments in Table 4.
DISCUSSION
Accurate screening of the early stages of VaD assumes
extreme importance, considering the high prevalence rates
of vascular cognitive impairment and the available primary
and secondary prevention strategies. The MMSE reveals
limitations in effective cognitive assessment of patients with
VaD because it does not include tasks for the evaluation
of the main area of compromise: executive dysfunction.
Thus, this study aims to validate the MoCA, as well as the
short version of the MoCA proposed by NINDS-CSN VCI
Harmonization Standards, as a 5-min protocol for cognitive
screening of VaD patients.
The results of the present study demonstrate that the
MoCA is a psychometrically valid and reliable instrument
for the cognitive screening of VaD patients. The internal
consistency was high, confirming the overall reliability of the
scale when used to examine Portuguese patients. Further-
more, the significant and positive correlations between the
MoCA scores and the MMSE scores are suggestive of con-
vergent validity. On the other hand, the significant and positive
correlations between each MoCA’s cognitive domain and the
MoCA total score are suggestive of construct-related validity.
Fig. 1. Receiver operating characteristics (ROC) curve analysis of
the MoCA full version (continuous line) and MMSE (dashed line) to
detect VaD patients. MoCA5Montreal Cognitive Assessment;
MMSE5Mini Mental State Examination; VaD5Vascular Dementia.
Fig. 2. Receiver operating characteristics (ROC) curve analysis of
the MoCA short version (continuous line) and MMSE (dashed line)
to detect VaD patients. MoCA5Montreal Cognitive Assessment;
MMSE5Mini Mental State Examination; VaD5Vascular Dementia.
Fig. 3. Receiver operating characteristics (ROC) curve analysis of the
MoCA full version (continuous line) and MoCA short version (dashed
line) to detect VaD patients. MoCA5Montreal Cognitive Assessment;
MMSE5Mini Mental State Examination; VaD5Vascular Dementia.
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Finally, all items showed a significant correlation with their
respective domains, with the exception of camel, second sub-
traction, place, and city items; these showed no significant
correlation with any domain, possibly due to the lower var-
iance of the items in this sample. Furthermore, we hypothesize
that the significant correlation found between the cube’s copy
item and executive function domain, beyond its correlation
with the visuospatial domain, is explained by the three-
dimensional nature of the drawing; it involves the use of
planning, sequencing and attentional skills.
For the MoCA’s discriminant capacity analysis, partici-
pants in the three groups (VaD, AD, and controls) were
matched for gender, age, and educational level; the two
clinical groups were also matched based on MMSE scores to
ensure comparable levels of severity of cognitive decline,
which we consider be essential for a reliable comparative
analysis, although it may have a minor effect on the correla-
tion coefficient between the two tests. The results showed that
both the full and short versions of the MoCA efficiently
discriminate the cognitively healthy adults from both clinical
groups. The performance of the healthy participants in
all MoCA cognitive domains was also significantly higher
than that of both clinical groups. However, no statistically
significant differences were found between VaD and AD
patients using both MoCA versions. Additionally, no differ-
ences were found between VaD and AD patients’ perfor-
mances in the different cognitive domains of the MoCA, or at
the level of some tasks’ sub-scores (clock drawing, naming
tasks, subtraction, and abstraction tasks). These findings
were convergent with the results of several prior studies,
which have failed to identify significant differences in
neuropsychological performance between VaD and AD
patients (Braaten, Parsons, McCue, Sellers, & Burns, 2006;
Desmond, 2004). Given the characteristics of the MoCA
(namely the more comprehensive assessment of major cog-
nitive domains as executive function, short-term memory,
languages abilities, and visuospatial processing) and the
findings of previous studies from our group, we hypothesized
that it could capture any difference in the cognitive profile of
these clinical groups. In the three validation studies devel-
oped by our research group (Freitas, Simo˜es, Maroˆco, Alves,
& Santana, 2012; Freitas, Simo˜es, Alves, Duro, & Santana,
manuscript submitted for publication; Freitas, Simo˜es, Alves,
& Santana, 2012), the MoCA’s sensitivity and discriminant
capacity at level of cognitive domains were well-demonstrated.
Thus, we believe that the undifferentiated performance
founded in this study may reflect the very close cognitive
profile between VaD and the AD patients more so than the
instrument’s inability to capture cognitive profiles.
The MoCA scores displayed excellent diagnostic accuracy
in the discrimination of VaD symptoms from age-related
changes in cognitively healthy elderly adults. The MoCA full
version scores exhibits an AUC significantly higher than that
of the MMSE’s AUC; this confirms the comparative superior
classificatory accuracy of the MoCA full version. The
optimal cutoff point on the MoCA for VaD patients, allowing
maximum sensitivity and specificity, was below 17 points.
This cutoff point is equivalent to the optimal cutoff for AD, as
established by our previous validation study (Freitas, et al.,
2012), as well as for Frontotemporal Dementia—behavioral-
variant patients (Freitas et al., submitted). With this cutoff
point, the MoCA showed good sensitivity (77%), excellent
specificity (97%) and PPV (96%), and good NPV (81%) and
classification accuracy (87%). With an optimal cutoff point
of below 26 points, the MMSE had consistently lower
respective values, namely in sensitivity (62%) and classifi-
catory accuracy (78%); this suggests that the MMSE is not a
good option as cognitive screening instrument for VaD,
as some authors have claimed (Hachinski et al., 2006;
Moorhouse & Rockwood, 2008; Pendlebury et al., 2010;
Roma´n, 2003). The main reasons for the MoCA’s higher
results at this level were the inclusion of the executive
function assessment and the consideration of more complex
tasks to measure short-term memory, language, attention,
concentration, working memory, and visuospatial skills.
The MoCA’s short version, proposed by NINDS-CSN
VCI Harmonization Standards (Hachinski et al., 2006) as
a 5-min protocol, also demonstrated excellent diagnostic
accuracy in discriminating VaD patients from the control
participants. The AUCs of the MoCA short and full versions
scores revealed no statistically significant differences, which
indicate that the MoCA short version is a valid abbreviated
option, useful in clinical settings with time constraints.
However, contrary to what occurred with the MoCA full
version, no significant differences were found in comparison
with the MMSE, although the MoCA short version’s ROC
curve fully include the curve for the MMSE, which indicate
that there is always a cutoff for the MoCA short version, with
Table 4. Diagnostic classification accuracy
Cutoff Sensitivity Specificity PPV NPV Classification accuracy
MoCA Total Scale , 17 77 97 96 81 87
MoCA Short Version , 8 85 88 88 86 87
MMSE , 26 62 94 91 71 78
Note. Sensitivity, Specificity, PPV, NPV, and Classification Accuracy values were expressed in percentage. Cutoff values indicate the minimum score
required for absence of signal.
MoCA5Montreal Cognitive Assessment (maximum score5 30); MoCA Short Version5 abbreviated version proposed by the NINDS-CSN VCI
Harmonization Standards criteria (maximum score5 12); MMSE5Mini Mental State Examination (maximum score5 30); AUC5 area under the
operating characteristic curve; PPV5 positive predictive value; NPV5 negative predictive value.
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higher sensitivity and specificity, for any cutoff chosen for
the MMSE. With an optimal cutoff point of below 8 points,
the MoCA short version showed high sensitivity (85%),
specificity (88%), PPV (88%), NPV (86%), and classification
accuracy (87%).
Due to the clinical heterogeneity of the VCI conditions,
this investigation was carried out in a homogeneous
sample of VaD patients. Patients who did not meet the criteria
for dementia or with mixed dementia classification were
excluded. The rigorous procedures adopted by the multi-
disciplinary team ensure the correct diagnosis of patients
according to the international criteria for VaD (Roma´n et al.,
1993). Major methodological strengths are the comprehen-
sive clinical evaluation with routine laboratory exams, strict
and rigorous imaging inclusion criteria, a comprehensive
neuropsychological assessment battery, and several exclu-
sion criteria for patients’ selection at the outset. Although
some studies conducted in cerebrovascular and cardiovas-
cular patients support the validity, reliability and sensitivity
of the MoCA, there are few previous studies using a homo-
geneous group of VaD patients to confirm those results and
no studies of validation of the MoCA short version.
The main strengths of this study are: (1) the homogeneity
of the VaD group; (2) the homogeneity of the samples in
terms of group size, gender, age, educational level, and
severity of cognitive decline in the clinical groups, which
allowed a more clear analysis and minimized the influence of
individual and methodological variables; (3) the above-
mentioned rigorous procedures adopted to ensure a probable
diagnosis of VaD and AD; (4) the well-characterized control
group, composed of cognitively healthy adult members of the
community; and (5) the reduction of inter-rater variability
because all participants were assessed by one of two expert
neuropsychologists.
Some limitations of this study must be addressed, how-
ever. First, as we intended to include and obtain results
from VaD patients, the generalization of these results to other
VCI subtypes should be performed with caution. Another
point to mention is that the scores of the MoCA short
version were computed after the complete administration
of the MoCA, rather than resulting from a second separate
administration. Despite there are no guidelines for the
administration order of short version items, in fact we did
not perform a separate administration of both versions. So
although we should to admit this procedure as a limitation,
we believe that the impact is limited because all additional
items are very brief tasks, with short and immediate answers
and the full MoCA is itself a short test. Another issue
that needs to be pointed out is the use of the MMSE as
both a cutoff for severity level’s restriction and a variable
of interest, making the results incorporating the MMSE
somewhat circular in nature. However, unfortunately it was
not possible to consider a third instrument for restricting the
severity level on the study due to constraints in the depart-
ment’s functioning and neuropsychological assessment
protocol currently used. The severity level’s restriction was
adopted because the MoCA was designed as a test for mild to
moderate cognitive decline. The complexity of the tasks that
compose the test is not adequate for patients with a more
pronounced cognitive decline. Finally, because this is the first
study that (i) validated the MoCA short version for VaD
patients, (ii) compared a shortened form to the original form
of the MoCA, and (iii) computed the cutoff points for both
MoCA short and full versions for the screening of VaD
patients, a comparative analysis of this results with other
studies cannot be performed.
Some future considerations: the need for (i) more studies
conducted in different cultural contexts other than the
Portuguese, (ii) studies with separate administrations of the
two versions of the MoCA; and (iii) studies with larger
sample sizes, which allow that the each clinical group is
divided into two subgroups, high and low scorers on the
MMSE, to further confirm the present findings.
In conclusion, the MoCA full and short versions proved
to be valid, reliable, sensitive and accurate measures of
cognitive impairment in VaD. Compared with the widely
used MMSE, this study produced evidence of the overall
superiority of both MoCA versions in terms of diagnostic
accuracy, confirming its great potential and usefulness for the
brief cognitive assessment of VaD patients.
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